Syndax Presents Constructive Revuforj ® (revumenib) Information in Acute Leukemias from A number of Trials, Together with the SAVE Mixture and AUGMENT-101 Trials, at 66th ASH Annual Assembly
“ 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of…
Investigational Epcoritamab (DuoBody ® CD3xCD20) Mixture Remedy Demonstrates Excessive Response Charges in Scientific Trial of Sufferers With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB):Outcomes present 96 p.c general response fee…
Investigational Epcoritamab (DuoBody ® CD3xCD20) Mixture Remedy Reveals Excessive Response Charges in Scientific Trial of Sufferers With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Knowledge offered on the 66th Annual Assembly and Exposition of the American…
Novel Mixture of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Better Management of Intravascular Hemolysis in Sufferers with Paroxysmal Nocturnal Hemoglobinuria In comparison with Ravulizumab
Head-to-head exploratory cohort of a Section 3 trial confirmed first-in-class poze-cemdi mixture…
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz ®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
” Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS)…
